In the phase III LEAP-002 study presented by Richard Finn, adding pembrolizumab to first line #Lenvatinib in HCC patients improved OS however, it did not meet the pre-specified efficacy boundary (p = 0.0185 for OS at Final Analysis). After median follow-up of 32.1m, the median OS with lenva + pembro was 21.2 mo vs 19.0 mo with lenva, and the HR, 0.840 P=0.0227, with no new safety signals observed. Additionally, the median OS of 19.0 mo with lenva monotherapy supports its role as a standard of care in 1L aHCC.
.png)